Integral Diagnostics Limited

ASX:IDX Stock Report

Market Cap: AU$858.4m

Integral Diagnostics Past Earnings Performance

Past criteria checks 1/6

Integral Diagnostics's earnings have been declining at an average annual rate of -50.5%, while the Healthcare industry saw earnings declining at 19% annually. Revenues have been growing at an average rate of 12.6% per year. Integral Diagnostics's return on equity is 0.8%, and it has net margins of 1.2%.

Key information

-50.5%

Earnings growth rate

-51.7%

EPS growth rate

Healthcare Industry Growth2.4%
Revenue growth rate12.6%
Return on equity0.8%
Net Margin1.2%
Next Earnings Update26 Aug 2025

Recent past performance updates

Recent updates

Slammed 29% Integral Diagnostics Limited (ASX:IDX) Screens Well Here But There Might Be A Catch

Feb 28
Slammed 29% Integral Diagnostics Limited (ASX:IDX) Screens Well Here But There Might Be A Catch

Some Investors May Be Worried About Integral Diagnostics' (ASX:IDX) Returns On Capital

Feb 21
Some Investors May Be Worried About Integral Diagnostics' (ASX:IDX) Returns On Capital

Shareholders Will Probably Hold Off On Increasing Integral Diagnostics Limited's (ASX:IDX) CEO Compensation For The Time Being

Nov 22
Shareholders Will Probably Hold Off On Increasing Integral Diagnostics Limited's (ASX:IDX) CEO Compensation For The Time Being

Integral Diagnostics' (ASX:IDX) Shareholders Will Receive A Smaller Dividend Than Last Year

Feb 20
Integral Diagnostics' (ASX:IDX) Shareholders Will Receive A Smaller Dividend Than Last Year

These 4 Measures Indicate That Integral Diagnostics (ASX:IDX) Is Using Debt Extensively

Dec 14
These 4 Measures Indicate That Integral Diagnostics (ASX:IDX) Is Using Debt Extensively

Should You Think About Buying Integral Diagnostics Limited (ASX:IDX) Now?

May 26
Should You Think About Buying Integral Diagnostics Limited (ASX:IDX) Now?

Integral Diagnostics (ASX:IDX) Is Paying Out Less In Dividends Than Last Year

Feb 28
Integral Diagnostics (ASX:IDX) Is Paying Out Less In Dividends Than Last Year

Integral Diagnostics Limited (ASX:IDX) Shares Could Be 38% Below Their Intrinsic Value Estimate

Feb 25
Integral Diagnostics Limited (ASX:IDX) Shares Could Be 38% Below Their Intrinsic Value Estimate

Shareholders Would Not Be Objecting To Integral Diagnostics Limited's (ASX:IDX) CEO Compensation And Here's Why

Oct 29
Shareholders Would Not Be Objecting To Integral Diagnostics Limited's (ASX:IDX) CEO Compensation And Here's Why

Does Integral Diagnostics (ASX:IDX) Deserve A Spot On Your Watchlist?

Sep 13
Does Integral Diagnostics (ASX:IDX) Deserve A Spot On Your Watchlist?

An Intrinsic Calculation For Integral Diagnostics Limited (ASX:IDX) Suggests It's 22% Undervalued

Jun 04
An Intrinsic Calculation For Integral Diagnostics Limited (ASX:IDX) Suggests It's 22% Undervalued

Should You Be Adding Integral Diagnostics (ASX:IDX) To Your Watchlist Today?

May 14
Should You Be Adding Integral Diagnostics (ASX:IDX) To Your Watchlist Today?

Is Integral Diagnostics Limited (ASX:IDX) A Smart Choice For Dividend Investors?

May 03
Is Integral Diagnostics Limited (ASX:IDX) A Smart Choice For Dividend Investors?

We Think Integral Diagnostics (ASX:IDX) Can Stay On Top Of Its Debt

Apr 16
We Think Integral Diagnostics (ASX:IDX) Can Stay On Top Of Its Debt

Is It Too Late To Consider Buying Integral Diagnostics Limited (ASX:IDX)?

Mar 27
Is It Too Late To Consider Buying Integral Diagnostics Limited (ASX:IDX)?

Is Integral Diagnostics Limited's (ASX:IDX) Stock's Recent Performance A Reflection Of Its Financial Health?

Mar 17
Is Integral Diagnostics Limited's (ASX:IDX) Stock's Recent Performance A Reflection Of Its Financial Health?

The Trends At Integral Diagnostics (ASX:IDX) That You Should Know About

Mar 07
The Trends At Integral Diagnostics (ASX:IDX) That You Should Know About

Here's What We Like About Integral Diagnostics' (ASX:IDX) Upcoming Dividend

Feb 25
Here's What We Like About Integral Diagnostics' (ASX:IDX) Upcoming Dividend

Is Integral Diagnostics Limited (ASX:IDX) Popular Amongst Institutions?

Feb 23
Is Integral Diagnostics Limited (ASX:IDX) Popular Amongst Institutions?

Have Insiders Been Selling Integral Diagnostics Limited (ASX:IDX) Shares?

Feb 13
Have Insiders Been Selling Integral Diagnostics Limited (ASX:IDX) Shares?

Integral Diagnostics Limited's (ASX:IDX) Intrinsic Value Is Potentially 46% Above Its Share Price

Feb 03
Integral Diagnostics Limited's (ASX:IDX) Intrinsic Value Is Potentially 46% Above Its Share Price

Revenue & Expenses Breakdown

How Integral Diagnostics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

ASX:IDX Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2449162817
30 Sep 24481-282716
30 Jun 24470-612715
31 Mar 24463-592621
31 Dec 23456-582620
30 Sep 23449-162617
30 Jun 23441252513
31 Mar 2341823246
31 Dec 2239521220
30 Sep 2237818210
30 Jun 2236115210
31 Mar 2236118210
31 Dec 2136022220
30 Sep 2135626220
30 Jun 2135131220
31 Mar 2133332210
31 Dec 2031532190
30 Sep 2029528180
30 Jun 2027623160
31 Mar 2026322180
31 Dec 1925021190
30 Sep 1924121210
30 Jun 1923221240
31 Mar 1922219230
31 Dec 1821117230
30 Sep 1820016220
30 Jun 1818915210
31 Mar 1818715210
31 Dec 1718515200
30 Sep 1718215200
30 Jun 1718015200
31 Mar 1717716190
31 Dec 1617516190
30 Sep 1617114180
30 Jun 1616811180
31 Mar 1616511170
31 Dec 1516211170
30 Sep 151578170
30 Jun 151515160
30 Jun 144310

Quality Earnings: IDX has a large one-off loss of A$6.1M impacting its last 12 months of financial results to 31st December, 2024.

Growing Profit Margin: IDX became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: IDX's earnings have declined by 50.5% per year over the past 5 years.

Accelerating Growth: IDX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: IDX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (8%).

Return on Equity

High ROE: IDX's Return on Equity (0.8%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/16 18:49
End of Day Share Price 2025/04/16 00:00
Earnings2024/12/31
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Integral Diagnostics Limited is covered by 23 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Thomas YeoBarrenjoey Markets Pty Limited
Saul HadassinBarrenjoey Markets Pty Limited
Benjamin BrayshawBarrenjoey Markets Pty Limited